STAT November 6, 2025
The question is whether a crop of startups can succeed in solving enduring scientific challenges
Biotech investors have not often looked at a balding head of hair and been struck with inspiration, even on the rare occasions when a new treatment is pitched to them. More often, they’ve rolled their eyes before moving on to the next slide deck from a new cancer drug developer or AI-focused startup.
But a funny thing happened last month: Two startups — Pelage Pharmaceuticals and Veradermics — raised a combined $270 million to develop treatments for a common form...
Today's Sponsors
Today's Sponsor